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EDITORIAL

EFFECT OF SARS-COV-2 GENETIC VARIATIONS IN
PERUVIAN COVID-19 TRANSMISSION
EFECTO DE LAS VARIANTES DE SARS-CoV-2 EN LA TRANSMISION DE COVID-19 EN EL PERÚ

EDITORIAL

Manuel J. Loayza-Alarico1,2,a,c , Jhony A. De La Cruz -Vargas1,3,b,d

SARS-CoV-2 is the coronavirus which causes the COVID-19 pandemic and is constitute by a rapidly
evolving RNA. This virus presents continuous genomic mutations as it is transmitted. The main focus
of the research about genetics of SARS-CoV-2 is whether any of these mutations have the potential to
significantly modify important viral properties, such as the mode or rate of transmission, or the ability to
cause increased lethality.Important mutations have already been reported in the United Kingdom, where
out of 25,000 genome sequencing, the D614G mutation in SARS-CoV-2 was identified, a mutation that
results in a displacement of aspartic acid with glycine at position 614 of the spike protein ( S) of the virus
that, although it is true, are not associated with greater mortality or clinical severity due to COVID-19, but
614G is associated with a higher viral load and a younger age of the patients.
The spike (S) protein of SARS-CoV-2 plays an important role in transmission. This is a large glycoprotein
containing the S1 and S2 subunits that mediates the cellular entry of the virus, binding to the receptor
for angiotensin converting enzyme 2 (ACE2) to enter the cell, therefore, mutations in this gene have
the potential to alter receptor binding affinity and infectivity, as well as viral immune evasion and
immunogenicity.
In December 2020, United Kingdom and South Africa reported two genetic variants of the SARS-CoV-2
virus have mutations in the Spike gene, the English variant has 7 mutations and two deletions (N501Y,
A570D, D614G, P681H, T716l, S982A , D1118H, deletion 69-70 and deletion 144-145) and the South African
variant showing 3 mutations in the RBD region (K417N, E484K, N501Y).
On January 8, 2021, in Peru, the presence of the British variant in a 37-year-old Peruvian woman was
notified. This variant has been designated as Variant of Concern 202012/01 (VOC), which has advantages
in the transmission of the disease. t is estimated that the VOC could have differences in the reproduction
number of 0.4 and 0.7 and the rate of the reproduction number between 1.4 and 1.8 that make it more
transmittable. Although it is true despite the variants that occur in the Spike protein, several vaccines
are directed to produce antibodies against many regions of this spike protein, so it is unlikely that these
changes will affect the efficacy of the vaccine. Likewise, the SARS-CoV-2 virus does not appear to mutate
as fast as the seasonal influenza virus which mutates every year where the vaccines that have so far
proven effective in trials are types that can be easily modified.
Faced with this situation, the domain of this variant of SARS-CoV-2 in the United Kingdom rapidly shifts
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from 30% in August to 70% in December. There
is a possibility that this British variant is already
circulating in Lima city and begins to appear in other
regions of the country.
It remains, then, to continue the genotyping of
SARS-CoV-2 of COVID-19 positive patients by the
National Institute of Health, wait for the entry of

vaccines to the country to start immunological
protection, but above all, to resume and extend
non-pharmacological protection measures such as
the correct use of a mask, social distancing, avoiding
being in conglomerates, or any other situation that is
perceived as a risk for the transmission of this disease.
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